Identification

Name
Velpatasvir
Accession Number
DB11613
Type
Small Molecule
Groups
Approved, Investigational
Description

Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [8]. Velpatasvir acts as a defective substrate for NS5A (Non-Structural Protein 5A), a non-enzymatic viral protein that plays a key role in Hepatitis C Virus replication, assembly, and modulation of host immune responses [3]. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as velpatasvir. Notably, velpatasvir has a significantly higher barrier to resistance than the first generation NS5A inhibitors, such as Ledipasvir and Daclatasvir, making it a highly potent and reliable alternative for treatment of chronic Hepatitis C [6].

In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Velpatasvir as first line therapy in combination with sofosbuvir for all six genotypes of Hepatitis C [8]. Velpatasvir is currently only available within a fixed dose combination product as Epclusa with Sofosbuvir, another direct acting antiviral. Goals of therapy for Epclusa include the intent to cure, or achieve a sustained virologic response (SVR), after 12 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality and risk of requiring a liver transplant [5].

Since June 2016, Velpatasvir has been available as a fixed dose combination product with Sofosbuvir, as the commercially available product Epclusa. Epclusa is the first combination HCV product indicated for the treatment of all genotypes of Hepatitis C with or without cirrhosis. It is also currently the most potent HCV antiviral medication on the market with a sustained virologic response (SVR) after 12 weeks of therapy of 93-99% depending on genotype and level of cirrhosis and a high barrier to resistance [8]. Both Canadian and American guidelines list Epclusa as a first line recommendation for all genotypes of HCV [8, 5].

Structure
Thumb
Synonyms
  • methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-4-yl}-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate
External IDs
GS 5816 / GS-5816 / GS5816
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
EpclusaVelpatasvir (100 mg) + Sofosbuvir (400 mg)TabletOralGilead Sciences2016-08-02Not applicableCanada
EpclusaVelpatasvir (100 mg) + Sofosbuvir (400 mg)Tablet, film coatedOralGilead Sciences Ireland Uc2016-07-06Not applicableEu
EpclusaVelpatasvir (100 mg/1) + Sofosbuvir (400 mg/1)Tablet, film coatedOralGilead Sciences2016-06-28Not applicableUs
VoseviVelpatasvir (100 mg/1) + Sofosbuvir (400 mg/1) + Voxilaprevir (100 mg/1)Tablet, film coatedOralGilead Sciences2017-07-18Not applicableUs
VoseviVelpatasvir (100 mg) + Sofosbuvir (400 mg) + Voxilaprevir (100 mg)TabletOralGilead Sciences2017-09-18Not applicableCanada
Categories
UNII
KCU0C7RS7Z
CAS number
1377049-84-7
Weight
Average: 883.019
Monoisotopic: 882.406460731
Chemical Formula
C49H54N8O8
InChI Key
FHCUMDQMBHQXKK-CDIODLITSA-N
InChI
InChI=1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1
IUPAC Name
(2S)-2-{[hydroxy(methoxy)methylidene]amino}-1-[(2S,5S)-2-(17-{2-[(2S,4S)-1-[(2R)-2-{[hydroxy(methoxy)methylidene]amino}-2-phenylacetyl]-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-21-oxa-5,7-diazapentacyclo[11.8.0.0^{3,11}.0^{4,8}.0^{14,19}]henicosa-1(13),2,4(8),6,9,11,14(19),15,17-nonaen-6-yl)-5-methylpyrrolidin-1-yl]-3-methylbutan-1-one
SMILES
[H][C@](N=C(O)OC)(C(C)C)C(=O)N1[C@@]([H])(C)CC[C@@]1([H])C1=NC2=C(N1)C1=CC3=C(C=C1C=C2)C1=C(CO3)C=C(C=C1)C1=CN=C(N1)[C@]1([H])C[C@]([H])(COC)CN1C(=O)[C@]([H])(N=C(O)OC)C1=CC=CC=C1

Pharmacology

Indication

Velpatasvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include therapy with Ribavirin.

When used in combination with Sofosbuvir as the combination product Epclusa, Velpatasvir is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or in combination with Ribavirin if associated with decompensated cirrhosis [Label].

Associated Conditions
Pharmacodynamics

Velpatasvir is a small molecule direct-acting antiviral used in the treatment of hepatitis C in combination with sofosbuvir. Velpatasvir prevents viral replication by inhibiting non-structural protein 5A (NS5A) [4].

At a dose 5 times the recommended dose, velpatasvir does not prolong QTc interval to any clinically relevant extent [Label].

Mechanism of action

Velpatasvir's mechanism of action is likely similar to other selective NS5A inhibitors which bind domain I of NS5A consisting of amino acids 33-202 [1]. NS5A inhibitors compete with RNA for binding at this site. It is also thought that NS5A inhibitors bind the target during its action in replication when the binding site is exposed [2]. Inhibition of NS5A is also known to produce redistribution of the protein to lipid droplets. The exact role of NS5A in RNA replication is not yet understood although it is known to be an important component.

TargetActionsOrganism
ANonstructural Protein 5A (NS5A)
inhibitor
Hepatitis C Virus (HCV)
Absorption

Oral bioavailability of 25-30% [3].

Volume of distribution

1.4-1.6 L/kg [3].

Protein binding

>99.5% bound to plasma proteins [Label].

Metabolism

Some metabolism by CYP2B6, CYP2C8, and CYP3A4 [3].

Route of elimination

94% excreted in feces with 77% as parent compound. 0.4% excreted in urine [Label].

Half life

15h [Label].

Clearance

Estimated 0.12 L/h/kg [A19175.

Toxicity

No indication of carcinogenicity or impairment of fertility/fetal viability [Label].

Affected organisms
  • Hepatitis C Virus
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of Velpatasvir can be decreased when combined with (R)-warfarin.
(S)-WarfarinThe metabolism of (S)-Warfarin can be decreased when combined with Velpatasvir.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Velpatasvir.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Velpatasvir.
5-androstenedioneThe metabolism of Velpatasvir can be decreased when combined with 5-androstenedione.
6-Deoxyerythronolide BThe metabolism of Velpatasvir can be decreased when combined with 6-Deoxyerythronolide B.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Velpatasvir.
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Velpatasvir.
AbirateroneThe metabolism of Velpatasvir can be decreased when combined with Abiraterone.
AcalabrutinibThe metabolism of Velpatasvir can be decreased when combined with Acalabrutinib.
Food Interactions
Not Available

References

General References
  1. Ascher DB, Wielens J, Nero TL, Doughty L, Morton CJ, Parker MW: Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep. 2014 Apr 23;4:4765. doi: 10.1038/srep04765. [PubMed:24755925]
  2. Targett-Adams P, Graham EJ, Middleton J, Palmer A, Shaw SM, Lavender H, Brain P, Tran TD, Jones LH, Wakenhut F, Stammen B, Pryde D, Pickford C, Westby M: Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action. J Virol. 2011 Jul;85(13):6353-68. doi: 10.1128/JVI.00215-11. Epub 2011 Apr 20. [PubMed:21507963]
  3. Mogalian E, German P, Kearney BP, Yang CY, Brainard D, Link J, McNally J, Han L, Ling J, Mathias A: Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects. Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02084-16. doi: 10.1128/AAC.02084-16. Print 2017 May. [PubMed:28193657]
  4. Lawitz E, Freilich B, Link J, German P, Mo H, Han L, Brainard DM, McNally J, Marbury T, Rodriguez-Torres M: A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus. J Viral Hepat. 2015 Dec;22(12):1011-9. doi: 10.1111/jvh.12435. Epub 2015 Jul 16. [PubMed:26183611]
  5. Myers RP, Shah H, Burak KW, Cooper C, Feld JJ: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):19-34. Epub 2015 Jan 13. [PubMed:25585348]
  6. Lawitz EJ, Dvory-Sobol H, Doehle BP, Worth AS, McNally J, Brainard DM, Link JO, Miller MD, Mo H: Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5368-78. doi: 10.1128/AAC.00763-16. Print 2016 Sep. [PubMed:27353271]
  7. Epclusa FDA Approval Announcement [Link]
  8. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017. [Link]
External Links
KEGG Drug
D10806
PubChem Compound
67683363
PubChem Substance
347828007
ChemSpider
34501056
ChEBI
133009
ChEMBL
CHEMBL3545062
PharmGKB
PA166163415
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Velpatasvir
FDA label
Download (338 KB)
MSDS
Download (243 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentHepatitis C Viral Infection / Lung Transplant Infection1
0RecruitingTreatmentHepatitis C Viral Infection / Transplant, Kidney1
1CompletedTreatmentChronic Hepatitis C Virus1
1CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
1CompletedTreatmentHepatitis C Virus (HCV) Infection1
1CompletedTreatmentHepatitis C Virus Infection1
1Not Yet RecruitingOtherHepatitis C Viral Infection / Swallowing Disorders1
1Not Yet RecruitingTreatmentHepatitis C Virus (HCV) Infection / Lung Transplant1
2Active Not RecruitingTreatmentChronic Hepatitis C Virus (HCV) Infection2
2Active Not RecruitingTreatmentHepatitis C Virus Infection1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection4
2CompletedTreatmentHepatitis C Viral Infection2
2CompletedTreatmentHepatitis C Virus Infection7
2RecruitingPreventionHeart Failure, Unspecified1
2RecruitingTreatmentHepatitis C Viral Infection1
2RecruitingTreatmentHepatitis C Viral Infection / Indolent B-cell Lymphoma1
2RecruitingTreatmentHepatitis C Virus Infection1
3Active Not RecruitingTreatmentHepatitis C Virus Infection1
3CompletedTreatmentHepatitis C Viral Infection2
3CompletedTreatmentHepatitis C Virus Infection13
4Active Not RecruitingTreatmentHCV Coinfection / Human Immunodeficiency Virus (HIV) / Liver Diseases1
4CompletedTreatmentHepatitis C Viral Infection / Thalassaemic disorders1
4CompletedTreatmentHepatitis C Virus Infection, Response to Therapy of / Human Immunodeficiency Virus (HIV)1
4Enrolling by InvitationTreatmentChronic Hepatitis C Virus (HCV) Infection1
4Not Yet RecruitingPreventionHepatitis C Viral Infection1
4Not Yet RecruitingPreventionHepatitis C Viral Infection / Respiratory Failure1
4Not Yet RecruitingScreeningHepatitis C Viral Infection1
4RecruitingHealth Services ResearchChronic Hepatitis C Virus (HCV) Infection / Opioid-use Disorder1
4RecruitingOtherHepatitis C Viral Infection / Transplantation Disease Transmission1
4RecruitingOtherHepatitis C Virus (HCV) Infection1
4RecruitingPreventionEnd Stage Liver Diseases / Hepatitis C Viral Infection1
4RecruitingTreatmentAwaiting Organ Transplant / Hepatitis C Viral Infection1
4RecruitingTreatmentBone Diseases, Metabolic / Chronic Hepatitis C Virus (HCV) Infection / Co-Infection / HIV-1-infection / Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) / Intravenous Drug Usage / Methadone Dependence / Opioid Dependence / Substance Abuse1
4RecruitingTreatmentChronic Hepatitis C Virus (HCV) Infection / Hepatitis C Viral Infection / Opiate Dependence1
4RecruitingTreatmentChronic Hepatitis C Virus (HCV) Infection / Lung Transplant1
4RecruitingTreatmentDrug Use / Hepatitis C Viral Infection1
4RecruitingTreatmentHepatitis C Viral Infection / HIV-1-infection / Liver Diseases1
4RecruitingTreatmentHepatitis C Viral Infection1
Not AvailableEnrolling by InvitationNot AvailableHepatitis C Viral Infection1
Not AvailableEnrolling by InvitationNot AvailableHepatitis C Virus Infection1
Not AvailableNot Yet RecruitingTreatmentCardiac Transplant / Hepatitis C Viral Infection1
Not AvailableRecruitingNot AvailableChronic Hepatitis C Virus (HCV) Infection1
Not AvailableRecruitingNot AvailableChronic Hepatitis C Virus (HCV) Infection / Human Immunodeficiency Virus (HIV)1
Not AvailableRecruitingNot AvailableComplications, Pregnancy / Hepatitis C Viral Infection / Vertical Disease Transmission1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral
Tablet, film coatedOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7964580No2009-03-262029-03-26Us
US8334270No2008-03-212028-03-21Us
US8633309No2009-03-262029-03-26Us
US8618076No2010-12-112030-12-11Us
US8735372No2008-03-212028-03-21Us
US8580765No2008-03-212028-03-21Us
US8889159No2009-03-262029-03-26Us
US9085573No2008-03-212028-03-21Us
US9284342No2010-09-132030-09-13Us
US8940718No2012-11-162032-11-16Us
US8575135No2012-11-162032-11-16Us
US8921341No2012-11-162032-11-16Us
US9585906No2008-03-212028-03-21Us
US9296782No2014-07-172034-07-17Us
US9757406No2014-01-302034-01-30Us
US9868745No2012-11-162032-11-16Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00153 mg/mLALOGPS
logP5.65ALOGPS
logP4.26ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)3.74ChemAxon
pKa (Strongest Basic)5.98ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area200.08 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity242.15 m3·mol-1ChemAxon
Polarizability97.91 Å3ChemAxon
Number of Rings9ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as naphthopyrans. These are compounds containing a pyran ring fused to a naphthalene moiety. Furan is a 6 membered-ring non-aromatic ring with five carbon and one oxygen atoms. Naphthalene is a polycyclic aromatic hydrocarbon made up of two fused benzene rings.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Naphthopyrans
Sub Class
Not Available
Direct Parent
Naphthopyrans
Alternative Parents
Dibenzopyrans / Valine and derivatives / Alpha amino acid amides / Phenylacetamides / 2-benzopyrans / Naphthalenes / Benzimidazoles / N-acylpyrrolidines / Alkyl aryl ethers / Pyrans
show 12 more
Substituents
Naphthopyran / Dibenzopyran / Valine or derivatives / Alpha-amino acid amide / Naphthalene / Phenylacetamide / 1-benzopyran / 2-benzopyran / Benzopyran / Alpha-amino acid or derivatives
show 28 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

1. Nonstructural Protein 5A (NS5A)
Kind
Protein
Organism
Hepatitis C Virus (HCV)
Pharmacological action
Yes
Actions
Inhibitor

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Sofosbuvir and Velpatasvir FDA Label [File]
  2. Sofosbuvir and Velpatasvir EMA Label [File]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) FDA Label [File]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
Transporter
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
Transporter
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
Transporter
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da

Drug created on August 05, 2016 17:48 / Updated on November 02, 2018 07:13